Table 4. The factors affecting seropositivity in the study population.
| Factors affecting seropositivity in the patient group (univariate analysis) | |||
|---|---|---|---|
| Characteristics | n (%) | Seropositivity (%) | p-value |
|
Age (years) <60 ≥60 |
291 (37.5) 485 (62.5) |
93.5 80.2 |
<0.001† |
|
Gender Female Male |
433 (55.8) 343 (44.2) |
88.0 81.6 |
0.015† |
|
BMI <25 kg/m2 ≥25 kg/m2 |
187 (30.7) 422 (69.3) |
88.8 86.3 |
0.435 |
|
Smoking No Ex-smoker Yes |
436 (59.2) 165 (22.4) 112 (17.8) |
85.3 87.3 83.0 |
0.577 |
|
Tumor type Breast Gastrointestinal Genitourinary Lung Other |
251 (32.3) 174 (22.4) 107 (13.8) 183 (23.6) 61 (7.9) |
88.0 86.2 84.1 80.9 85.2 |
0.335 |
|
Treatment type (active) No treatment Chemotherapy Targeted or IO |
350 (45.1) 309 (39.8) 117 (15.1) |
91.1 78.6 84.6 |
<0.001† |
|
Chemotherapy Never Not in the last 3 months Active |
152 (19.6) 315 (40.6) 309 (39.8) |
87.5 90.5 78.6 |
<0.001† |
|
Immunotherapy (IO) Yes No |
42 (5.4) 734 (94.6) |
85.7 85.1 |
0.920 |
|
Targeted therapies Yes No |
178 (22.9) 598 (77.1) |
86.0 84.9 |
0.811 |
|
Hormone therapy Yes No |
209 (26.9) 567 (73.1) |
87.1 84.5 |
0.426 |
|
Comorbidities No Yes |
373 (48.1) 403 (51.9) |
86.9 83.6 |
0.225 |
|
Stage Nonmetastatic Metastatic |
378 (48.7) 398 (51.3) |
90.7 79.9 |
<0.001† |
| Factors affecting seropositivity in the control group (univariate analysis) | |||
|---|---|---|---|
| Characteristics | n (%) | Seropositivity (%) | p-value |
|
Age (years) <60 ≥60 |
614 (85.9) 101 (14.1) |
98.4 92.1 |
<0.001† |
|
Gender Female Male |
398 (55.7) 317 (44.3) |
98.0 96.8 |
0.347 |
|
BMI <25 kg/m2 ≥25 kg/m2 |
118 (30.5) 269 (69.5) |
97.5 97.0 |
0.435 |
|
Smoking No Ex-smoker Yes |
428 (72.2) 16 (2.7) 149 (25.1) |
97.2 93.8 97.3 |
0.711 |
|
Comorbidities No Yes |
544 (76.1) 171 (23.9) |
97.8 96.5 |
0.399 |
†
Statistically significant results.
IO: Immunotherapy.